Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2003;41:390-391
Published online before print February 24, 2003, doi: 10.1161/01.HYP.0000060688.57053.7E
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/3/390    most recent
01.HYP.0000060688.57053.7Ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrario, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrario, C. M.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Structure
Right arrow ACE/Angiotension receptors
Right arrow Hypertrophy
Right arrow Clinical Studies

(Hypertension. 2003;41:390.)
© 2003 American Heart Association, Inc.


Editorial Commentary

Commentary on Tikellis et al

There Is More to Discover About Angiotensin-Converting Enzyme

Carlos M. Ferrario

From the Hypertension and Vascular Disease Center, Wake Forest University Health Science Center, Winston-Salem, NC.

Correspondence to Carlos M. Ferrario, MD, Hypertension and Vascular Disease Center, Wake Forest University Health Science Center, Winston-Salem, NC 27154. E-mail cferrari@wfubmc.edu


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Irvine H. Page used to say that the regular occurrence of constant amounts of a substance in the body is seldom without purpose and that organisms exhibit an inner economy and prudence by using one substance for several functions. Almost 50 years later, we are now challenged again to decipher just how complicated and how physiologically relevant are newly discovered biochemical pathways contributing to the formation of biologically active forms of angiotensin peptides. The need to revisit the role of angiotensin-forming enzymes was stimulated by the finding of a new gene encoding a protein having highest homology to the testes-specific isoform of angiotensin-converting enzyme (ACE).1,2

In 1991, we first suggested3 that angiotensin II (Ang II) should be viewed as one but not the sole principal product of the renin-angiotensin system. The proposal was based on the characterization of biological actions of the heptapeptide angiotensin-(1–7) [Ang-(1–7)] and its forming enzymes. There was reluctance to accept this concept in part because the potential role of Ang-(1–7) in cardiovascular regulation was still at an embryonic stage, there was little evidence that Ang II could act at more than one receptor, and a full characterization of other enzymic pathways for angiotensin peptide formation had not been achieved yet. The situation is quite different today; a growing body of literature now implicates Ang-(1–7)3–7 and angiotensin IV (Ang-3–8)8 as components of the system, and additional work has identified chymase, prolyl endopeptidase 24.26, neutral endopeptidase 24.11, metalloendopeptidase 24.15,9 and now a homologue of ACE10 as angiotensin prohormone . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
HypertensionHome page
S. Giunti, D. Barit, and M. E. Cooper
Mechanisms of Diabetic Nephropathy: Role of Hypertension
Hypertension, October 1, 2006; 48(4): 519 - 526.
[Full Text] [PDF]


Home page
Circ. Res.Home page
U. Danilczyk and J. M. Penninger
Angiotensin-Converting Enzyme II in the Heart and the Kidney
Circ. Res., March 3, 2006; 98(4): 463 - 471.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan, and C. M. Ferrario
Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors
Hypertension, May 1, 2004; 43(5): 970 - 976.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. M. Carey
Angiotensin Type-1 Receptor Blockade Increases ACE 2 Expression in the Heart
Hypertension, May 1, 2004; 43(5): 943 - 944.
[Full Text] [PDF]


Home page
HypertensionHome page
M. Ye, J. Wysocki, P. Naaz, M. R. Salabat, M. S. LaPointe, and D. Batlle
Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice: A Renoprotective Combination?
Hypertension, May 1, 2004; 43(5): 1120 - 1125.
[Abstract] [Full Text] [PDF]